Johnson & Johnson (NYSE:JNJ) is one of Goldman Sachs top healthcare stocks. On March 10, Johnson & Johnson (NYSE:JNJ) announced the submission of a Type II variation application to the European Medicines Agency. The company is seeking approval of TECVAYLI (teclistamab) as a potential treatment for relapsed and refractory multiple Myeloma. Johnson & Johnson (JNJ) Targets Opportunities around Multiple Myeloma with TECVAYLI The company hopes to make TECVAYLI available at a time when patients with multiple m ...